Lewis R. Vidler

Lewis R. Vidler

Auto-generated profile, based on publicly available information

Lewis R. Vidler

Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
LVLewis R. Vidler
Lewis R. Vidler
NBNathan Brown
Nathan Brown
SKStefan Knapp
Stefan Knapp
SHSwen Hoelder
Swen Hoelder
Bromodomains are readers of the epigenetic code that specifically bind acetyl-lysine containing recognition sites on proteins. Recently the BET family of bromodomains has been demonstrated to be druggable through the discovery of potent inhibitors, sparking an interest in protein–protein interaction inhibitors that directly target gene transcription. Here, we assess the druggability of diverse members of the bromodomain family using SiteMap and show that there are significant differences in predicted druggability. Furthermore, we trace these differences in druggability back to unique amino acid signatures in the bromodomain acetyl-lysine binding sites. These signatures were then used to generate a new classification of the bromodomain family, visualized as a classification tree. This represents the first analysis of this type for the bromodomain family and can prove useful in the discovery of inhibitors, particularly for anticipating screening hit rates, identifying inhibitors that can be explored for lead hopping approaches, and selecting proteins for selectivity screening.

3 October 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
LVLewis R. Vidler
Lewis R. Vidler
PFPanagis Filippakopoulos
Panagis Filippakopoulos
OFOleg Fedorov
Oleg Fedorov
SPSarah Picaud
Sarah Picaud
SMSarah Martin
Sarah Martin
SHSwen Hoelder
Swen Hoelder
Bromodomains (BRDs) are epigenetic readers that recognize acetylated-lysine (KAc) on proteins and are implicated in a number of diseases. We describe a virtual screening approach to identify BRD inhibitors. Key elements of this approach are the extensive design and use of substructure queries to compile a set of commercially available compounds featuring novel putative KAc mimetics and docking this set for final compound selection. We describe the validation of this approach by applying it to the first BRD of BRD4. The selection and testing of 143 compounds lead to the discovery of six novel hits, including four unprecedented KAc mimetics. We solved the crystal structure of four hits, determined their binding mode, and improved their potency through synthesis and the purchase of derivatives. This work provides a validated virtual screening approach that is applicable to other BRDs and describes novel KAc mimetics that can be further explored to design more potent inhibitors.

26 February 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
LDLudovic Drouin
Ludovic Drouin
SMSally McGrath
Sally McGrath
LVLewis R. Vidler
Lewis R. Vidler
Apirat ChaikuadApirat Chaikuad
Apirat Chaikuad
OMOctovia Monteiro
Octovia Monteiro
SHSwen Hoelder
Swen Hoelder
The bromodomain containing proteins BAZ2A/B play essential roles in chromatin remodeling and regulation of noncoding RNAs. We present the structure based discovery of a potent, selective, and cell active inhibitor 13 (BAZ2-ICR) of the BAZ2A/B bromodomains through rapid optimization of a weakly potent starting point. A key feature of the presented inhibitors is an intramolecular aromatic stacking interaction that efficiently occupies the shallow bromodomain pockets. 13 represents an excellent chemical probe for functional studies of the BAZ2 bromodomains in vitro and in vivo.

24 June 2009 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
MJMaite Jauregui
Maite Jauregui
WPWilliam S. Perry
William S. Perry
CAClémence Allain
Clémence Allain
LVLewis R. Vidler
Lewis R. Vidler
MWMichael C. Willis
Michael C. Willis
SFStephen Faulkner
Stephen Faulkner
Alkyne appended lanthanide complexes derived from DO3A undergo copper catalysed cycloaddition reactions with azides to form triazole appended complexes: coordination of one of the triazole nitrogen atoms to the metal centre changes the local coordination environment and the spectroscopic properties of the complex.

21 April 2020 in Chemistry – A European Journal
Verified
Journal Article
Open access
PDF file
TDThomas D. Downes
Thomas D. Downes
SJS. Paul Jones
S. Paul Jones
HKHanna F. Klein
Hanna F. Klein
MWMary C. Wheldon
Mary C. Wheldon
MAMasakazu Atobe
Masakazu Atobe
POPeter O'Brien
Peter O'Brien
Fragment‐based drug discovery is now widely adopted for lead generation in the pharmaceutical industry. However, fragment screening collections are often predominantly populated with flat, 2D molecules. Herein, we describe a workflow for the design and synthesis of 56 3D disubstituted pyrrolidine and piperidine fragments that occupy under‐represented areas of fragment space (as demonstrated by a principal moments of inertia (PMI) analysis). A key, and unique, underpinning design feature of this fragment collection is that assessment of fragment shape and conformational diversity (by considering conformations up to 1.5 kcal mol−1 above the energy of the global minimum energy conformer) is carried out prior to synthesis and is also used to select targets for synthesis. The 3D fragments were designed to contain suitable synthetic handles for future fragment elaboration. Finally, by comparing our 3D fragments with six commercial libraries, it is clear that our collection has high three‐dimensionality and shape diversity.

10 July 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
LVLewis R. Vidler
Lewis R. Vidler
IWIan A. Watson
Ian A. Watson
BMBrandon J. Margolis
Brandon J. Margolis
DCDavid J. Cummins
David J. Cummins
MBMichael Brunavs
Michael Brunavs
Biochemical assay interference is becoming increasingly recognized as a significant waste of resource in drug discovery, both in industry and academia. A seminal publication from Baell and Holloway raised the awareness of this issue, and they published a set of alerts to identify what they described as PAINS (pan-assay interference compounds). These alerts have been taken up by drug discovery groups, even though the original paper had a somewhat limited data set. Here, we have taken Lilly’s far larger internal data set to assess the PAINS alerts on four criteria: promiscuity (over six assay formats including AlphaScreen), compound stability, cytotoxicity, and presence of a high Hill slope as a surrogate for non-1:1 protein–ligand binding. It was found that only three of the alerts show pan-assay promiscuity, and the alerts appear to encode primarily AlphaScreen promiscuous molecules. Although not enriching for pan-assay promiscuity, many of the alerts do encode molecules that are unstable, show cytotoxicity, and increase the prevalence of high Hill slopes.